Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12844009 | 0.93 | CALM1 (0.61) | CALM1KDM4EPOLBATMCA2 | |
| SCHEMBL623585 | 0.90 | CALM1 (0.57) | CALM1GAAMAPTNPC1RAB9A | |
| SCHEMBL8295694 | 0.89 | CALM1 (0.67) | CALM1KDM4EGAAMAPTPOLB | |
| SCHEMBL427541 | 0.88 | ATM (0.68) | KDM4EMAPTSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL12233056 | 0.87 | CALM1 (0.55) | CALM1KDM4ENPC1RAB9ASMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL10556485 | 0.86 | ATM (0.66) | KDM4EMAPTSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL8867447 | 0.86 | CALM1 (0.67) | CALM1KDM4EGAAMAPTNPC1 | |
| SCHEMBL3938308 | 0.86 | CALM1 (0.67) | CALM1KDM4EGAAMAPTPOLB | |
| SCHEMBL1251843 | 0.86 | KDM4E (0.77) | CALM1KDM4EGAAMAPTPOLB | |
| SCHEMBL29543507 | 0.86 | KDM4E (0.77) | CALM1KDM4EGAAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130273-A1 | METHOD FOR THE DEACYLATION AND/OR DEALKYLATION OF COMPOUNDS | UNIVERSITEIT ANTWERPEN (BE) | 2021-05-06 | — | — | US | disclosed |
| US-10869822-B2 | Compositions for treatment of dermatological diseases and conditions and methods of use thereof | DermaMedics, LLC (US) | 2020-12-22 | — | — | US | disclosed |
| WO-2019025535-A1 | METHOD FOR THE DEACYLATION AND/OR DEALKYLATION OF COMPOUNDS | UNIVERSITEIT ANTWERPEN (BE) | 2019-02-07 | — | — | WO | disclosed |
| US-20180235859-A1 | Compositions for Treatment of Dermatological Diseases and Conditions and Methods of Use Thereof | DermaMedics, LLC | 2018-08-23 | — | — | US | disclosed |
| US-9980887-B2 | Compositions for use in treatment of hyperpigmentation and methods of use thereof | DermaMedics, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3238696-A1 | METHODS AND COMPOSITIONS FOR TREATING DERMATOLOGICAL DISEASES AND CONDITIONS | Therametics, Llc (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9622950-B2 | Compositions for use in treatment of dermatological diseases and conditions | DermaMedics, LLC (US) | 2017-04-18 | — | — | US | disclosed |
| US-9616006-B2 | Methods and compositions for treating dermatological diseases and conditions | DermaMedics, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160346180-A1 | Compositions for Use in Treatment of Dermatological Diseases and Conditions and Methods of Use Thereof | DERMAMEDICS LLC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150065490-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-7393827-B2 | Pharmaceutical compositions and methods for restoring β-cell mass and function | DIAKINE THERAPEUTICS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393827-B2 | Pharmaceutical compositions and methods for restoring β-cell mass and function | DIAKINE THERAPEUTICS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| WO-2008011518-A2 | ENCAPSULATION SYSTEM | DIAKINE THERAPEUTICS, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007146786-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING B-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| WO-2006074051-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | CALM1 792/4885KDM4E 3889/4885GAA 3278/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | CALM1 1278/4885KDM4E 3026/4885GAA 1059/4885 |
| US-20210130273-A1 | METHOD FOR THE DEACYLATION AND/OR DEALKYLATION OF COMPOUNDS | HAAO, TDO2, HPD | CALM1 3017/4885KDM4E 470/4885GAA 998/4885 |
| US-20150065490-A1 | ORGANIC COMPOUNDS | ADRB2, ADRA2C, ADRB1 | CALM1 1740/4885KDM4E 4160/4885GAA 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.